Drugs / Henatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01416623 | Sep 2010 → Dec 2012 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Henatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01416623 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL1277072 ↗1“tyrosine kinase inhibitor” NCT01416623 ↗ |
| Modality | Small molecule | — CHEMBL1277072 ↗ |
| Route | Oral | “novel oral multitargeted tyrosine kinase inhibitor” NCT01416623 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL1277072 ↗ |